Biotech's biggest funding vacuum: $10-15M meaningful Seed rounds nobody provides
PatrickKidger · x · 2026-11-13
alexschbrt argues biotech's biggest funding vacuum is firms that can assemble meaningful Seed rounds: between lots of pre-seed/small-seed investors and large investors demanding robust data packages lies a gap. Exciting technologies lack resources for validation; given advances in AI and bio infrastructure, $10–15M rounds could be transformative for many companies.
More from Venture
- Founder asks: are top VCs really funding all-non-technical teams? — generativist · 2026-11-13
- Why didn't VCs push for IPOs in 2025? SPV fee addiction suspected — PTrubey · 2026-11-13
- Anthropic's Q3: revenue up 47% but compute costs jumped 77%, swinging to an operating loss — bigdata · 2026-11-13
- AI wealth's 'third wave' of philanthropy: ~$37B a year, best spent catalyzing markets — RishiBommasani · 2026-11-13
- NYT: Jensen Huang hires Paul Weiss law firm after exit from NVIDIA — zephyr_z9 · 2026-11-13
- AI Shopping Agents Could Break the 20-25% Commission Marketplace Model — julianweisser · 2026-11-13